Latest news with #Dasatinib
&w=3840&q=100)
Business Standard
08-05-2025
- Business
- Business Standard
Biocon Q4FY25 results: Consolidated net profit rises 153% to ₹344 crore
Bengaluru-based biopharma major Biocon on Thursday reported a 153 per cent year-on-year (YoY) rise in consolidated net profit to ₹344 crore for the fourth quarter of FY25, compared to ₹ 136 crore in Q4 FY24. The company's profit before tax (PBT) stood at ₹487 crore, up 53 per cent YoY. The Board has also approved a plan to raise up to ₹4,500 crore through various modes, including qualified institutional placement, rights issue, or other permissible routes. The growth was attributed to robust performance across the company's generics, biologics, and research services businesses. Biocon's total consolidated revenue for Q4 FY25 was ₹4,454 crore, up from ₹ 3,966 crore in Q4 FY24. EBITDA stood at ₹1,115 crore, marking a 16 per cent rise, with a maintained margin of 25 per cent. For the full financial year FY25, revenue from operations grew 9 per cent to ₹11,537.8 crore, compared to ₹ 10,588 crore in FY24. However, net profit for the year declined marginally by 0.9 per cent to ₹1,013.3 crore from ₹1,022.5 crore. The generics business, which includes active pharmaceutical ingredients (APIs) and generic formulations, posted a 46 per cent YoY revenue increase to ₹1,048 crore. Syngene, Biocon's research arm, recorded an 11 per cent growth in revenue to ₹1,018 crore. Biocon Biologics, the company's biosimilars segment, reported 9 per cent revenue growth to ₹2,463 crore. 'The launch of Liraglutide in the UK marked our entry into the GLP-1 therapy segment. Our biosimilars continue to build global market share, with four biosimilars generating over $200 million in FY25. This quarter also saw Syngene expand its biologics manufacturing footprint through the acquisition of a US facility,' said Kiran Mazumdar-Shaw, Chairperson, Biocon Group. Siddharth Mittal, CEO and Managing Director of Biocon, attributed the generics division's growth to new launches such as Lenalidomide and Dasatinib in the US, supported by moderate growth in APIs. 'We are focused on strategically expanding our differentiated GLP-1 portfolio into new markets, positioning us for long-term growth. We also expect a recovery in the API business in FY26, aided by cost improvements, operational efficiencies, and new capacity additions,' he said. Shreehas Tambe, CEO and Managing Director of Biocon Biologics, said performance was driven by market share gains in the US and key tender wins in emerging markets. 'We are well positioned to launch five new products in the next 12–18 months and expand patient access,' he added. Peter Bains, CEO and Managing Director of Syngene International, noted that Q4 revenue grew 11 per cent YoY and 8 per cent sequentially, crossing ₹1,000 crore in quarterly revenue for the first time. 'While global market dynamics remain uncertain, the positive momentum that drove Syngene's growth in the latter half of FY25 is expected to continue into FY26,' he said. The Board has recommended a final dividend of ₹0.50 per share (10 per cent of face value) for the financial year ended 31 March 2025. Biocon also secured 12 regulatory approvals and made several filings for biosimilars including bUstekinumab, bDenosumab, and bAflibercept across multiple countries, aiming to expand patient access globally. The Q4 results were announced after market hours. Biocon shares closed 3 per cent lower at ₹334.60 apiece on Thursday.
Business Upturn
08-05-2025
- Business
- Business Upturn
Biocon Q4FY25 results: Net profit jumps 153% YoY to Rs 344 crore; revenue rises 12% to Rs 4,454 crore
By News Desk Published on May 8, 2025, 19:50 IST Biocon Limited reported a strong financial performance for the quarter and financial year ended March 31, 2025. For Q4FY25, consolidated revenue came in at Rs 4,454 crore, marking a 12% year-on-year (YoY) increase. On a like-for-like basis, the revenue grew 15% YoY after adjusting for revenues from Branded Formulations India (BFI). EBITDA rose 16% YoY to Rs 1,115 crore with an EBITDA margin of 25%. Core EBITDA, excluding R&D and other adjustments, came in at Rs 1,363 crore with a margin of 31%. The company posted a net profit of Rs 344 crore in Q4FY25, a significant 153% YoY jump. On a like-for-like basis, the net profit rose 162% YoY. Profit before tax (PBT) surged 53% YoY to Rs 487 crore. Segmental performance Generics : Revenue rose 46% YoY to Rs 1,048 crore, driven by strong contributions from Lenalidomide and Dasatinib launches in the U.S. : Revenue rose 46% YoY to Rs 1,048 crore, driven by strong contributions from Lenalidomide and Dasatinib launches in the U.S. Biosimilars : Revenue increased 4% YoY to Rs 2,463 crore. On an adjusted basis, it rose 9% YoY. : Revenue increased 4% YoY to Rs 2,463 crore. On an adjusted basis, it rose 9% YoY. Research Services (Syngene): Revenue climbed 11% YoY to Rs 1,018 crore. Full-year FY25 highlights For the full year, Biocon reported: Total revenue : Rs 16,470 crore, up 5% YoY (8% like-for-like) : Rs 16,470 crore, up 5% YoY (8% like-for-like) EBITDA : Rs 4,374 crore, up 5% YoY : Rs 4,374 crore, up 5% YoY Net profit: Rs 1,013 crore, down 1% YoY; however, like-for-like net profit increased 30% Dividend and capital plans The Board recommended a final dividend of Rs 0.50 per share. Additionally, it approved raising up to Rs 4,500 crore through various financial instruments for debt repayment and strategic investments. Strategic developments Biocon Biologics launched its fifth biosimilar, Yesintek (bUstekinumab), in the U.S. and Germany, and secured a U.S. market entry for Yesafili (bAflibercept). The company also partnered with Civica Inc. to increase access to insulins. Syngene crossed Rs 1,000 crore in quarterly revenue for the first time and acquired a biologics manufacturing facility in the U.S., expanding its CDMO capabilities. Biocon has also initiated an evaluation of a potential merger between Biocon Limited and Biocon Biologics. Sustainability Biocon and Biocon Biologics were both included in the S&P Global Sustainability Yearbook 2025, with Biocon ranked among the top 5% in the Biotechnology sector. News desk at
Time of India
23-04-2025
- Business
- Time of India
Aurobindo Pharma arm gets USFDA nod for generic blood cancer drug
Aurobindo Pharma on Wednesday said its wholly- owned arm Eugia Pharma Specialities Ltd has received final approval from the USFDA to manufacture and market its generic version of Dasatinib tablets indicated in certain types of cancer of bone marrow and blood. The approval by the US Food & Drug Administration (USFDA) is for manufacturing and marketing of Dasatinib tablets of strengths 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, Aurobindo Pharma said in a regulatory filing. These are bioequivalent and therapeutically equivalent to the reference listed drug Sprycel Tablets in the same strengths, of Bristol-Myers Squibb Company (BMS), it added. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like If You Eat Ginger Everyday for 1 Month This is What Happens Tips and Tricks Undo The product is expected to be launched in Q1FY26, Aurobindo Pharma said. The approved product has an estimated market size of USD 1.8 billion for the 12 months ended February 2025, it said citing IQVIA MAT data.
&w=3840&q=100)
Business Standard
23-04-2025
- Business
- Business Standard
Aurobindo Pharma in focus: Why has the stock gained 3% in trade today?
Aurobindo Pharma Ltd share price: Shares of Aurobindo Pharma gained 2.9 per cent in trade, registering an intraday high at ₹1,222.9 on the BSE. The up move in the stock came after the company arm Eugia Pharma Specialities, received final approval from the US Food & Drug Administration (US FDA) to manufacture and market Dasatinib tablets. According to the filing, Dasatinib tablets are indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib and adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy. At 12:22 PM, Aurobindo Pharma shares were trading 2.65 per cent higher at ₹1,219.6 per share on the BSE. In comparison, the BSE Sensex was up 0.20 per cent at 79,757.46. The market capitalisation of the company stood at ₹70,834.57 crore. The 52-week high of the stock was at ₹1,592.55 per share and 52-week low of the stock was at ₹994.35 per share. Eugia Pharma will be manufacturing Dasatinib Tablets of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, of Bristol-Myers Squibb Company (BMS). The product is expected to be launched in Q1FY26. The approved product has an estimated market size of $1.8 billion for the twelve months ending February 2025, according to IQVIA MAT. This is the 181st ANDA approval (including 9 tentative approvals received) out of Eugia Pharma Specialities Group (EPSG) facilities, manufacturing both oncology oral and sterile specialty products. ALSO READ | Bharti Hexacom hits all time high after 400 MHz deal with with Adani firm About Aurobindo Pharma Aurobindo Pharma is an integrated global pharmaceutical company headquartered in Hyderabad, India. The company develops, manufactures, and commercialises a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company has 30+ manufacturing and packaging facilities. Its robust product portfolio is spread over seven major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and AntiAllergic, supported by a strong R&D set-up.
Business Standard
23-04-2025
- Business
- Business Standard
Aurobindo Pharma rallies after arm receives USFDA nod for Dasatinib tablets
Aurobindo Pharma rose 1.81% to Rs 1,209.60 after its wholly owned subsidiary, Eugia Pharma Specialities, received final approval from the U.S. Food and Drug Administration (USFDA) to manufacture and market Dasatinib Tablets. The drug is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets by Bristol-Myers Squibb Company (BMS). Dasatinib is approved for treating Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in adults and children, including newly diagnosed cases. It is also indicated for Ph+ CML with resistance or intolerance to prior therapies like imatinib and for Ph+ acute lymphoblastic leukemia (ALL) with treatment resistance or intolerance. The approved product has an estimated market size of US$ 1.8 billion for the twelve months ending February 2025, according to IQVIA MAT. This marks the 181st ANDA approval (including 9 tentative approvals) from Eugia Pharma Specialties Group (EPSG) facilities, which manufacture both oncology oral and sterile specialty products. Aurobindo Pharma is an integrated global pharmaceutical company headquartered in Hyderabad, India. The company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients globally in over 150 countries. The companys consolidated net profit fell 9.7% to Rs 845.81 crore in Q3 FY25 as compared with Rs 936.26 crore in Q3 FY24. Net sales increased 8.6% YoY to Rs 7,893.15 crore during the quarter ended 31st December 2024.
